TNFRSF1A and autoimmune disease: In the treatment of autoimmune disease models, sTNF inhibitors or TNFR1 antagonists (e.g., XPro1595 and XENP1595 (PEGylated derivative), DMS5540, ATROSAB, TROS and R1antTNF) have been shown to specifically block the sTNF/TNFR1 signal while leaving the TNFR2 signaling pathway intact, indicating a dominating role sTNF towards TNFR1 compared to TNFR2 (48, 56–60).